| 1 | Current systematic reviews and meta-analyses of COVID-19显示文摘BACKGROUND Coronavirus disease 2019(COVID-19)has left a significant impact on the world's health,economic and political systems;as of November 20,2020,more than 57 million people have been infected worldwide,with over 1.3 million deaths.While the global spotlight is currently focused on combating this pandemic through means ranging from finding a treatment among existing therapeutic agents to inventing a vaccine that can aid in halting the further loss of life.AIM To collect all systematic reviews and meta-analyses published related to COVID-19 to better identify available evidence,highlight gaps in knowledge,and elucidate further meta-analyses and umbrella reviews that are yet to be performed.METHODS We explored studies based on systematic reviews and meta-analyses with the keyterms,including severe acute respiratory syndrome(SARS),SARS virus,coronavirus disease,COVID-19,and SARS coronavirus-2.The included studies were extracted from Embase,Medline,and Cochrane databases.The publication timeframe of included studies ranged between January 01,2020,to October 30,2020.Studies that were published in languages other than English were not considered for this systematic review.The finalized full-text articles are freely accessible in the public domain.RESULTS Searching Embase,Medline,and Cochrane databases resulted in 1906,669,and 19 results,respectively,that comprised 2594 studies.515 duplicates were subsequently removed,leaving 2079 studies.The inclusion criteria were systematic reviews or meta-analyses.860 results were excluded for being a review article,scope review,rapid review,panel review,or guideline that produced a total of 1219 studies.After screening articles were categorized,the included articles were put into main groups of clinical presentation,epi-demiology,screening and diagnosis,severity assessment,special populations,and treatment.Subsequently,there was a second subclassification into the following groups:gastrointestinal,cardiovascular,neurological,stroke,thrombosis,anosmia and dysgeusia,ocular manifestations,nephrology,cutaneous manifestations,D-dimer,lymphocyte,anticoagulation,antivirals,convalescent plasma,immunosuppressants,corticosteroids,hydroxychloroquine,renin-angiotensin-aldosterone system,technology,diabetes mellitus,obesity,pregnancy,children,mental health,smoking,cancer,and transplant.CONCLUSION Among the included articles,it is clear that further research is needed regarding treatment options and vaccines.With more studies,data will be less heterogeneous,and statistical analysis can be better applied to provide more robust clinical evidence.This study was not designed to give recommendations regarding the management of COVID-19. | Mahmoud Nassar Nso Nso Mostafa Alfishawy Anastasia Novikov Salim Yaghi Luis Medina Bahtiyar Toz Sofia Lakhdar Zarwa Idrees Yungmin Kim Dawa Ongyal Gurung Raheel S Siddiqui David Zheng Mariam Agladze Vikram Sumbly Jasmine Sandhu Francisco Cuevas Castillo Nadya Chowdhury Ravali Kondaveeti Sakil Bhuiyan Laura Guzman Perez Riki Ranat Carlos Gonzalez Harangad Bhangoo John Williams Alaa Eldin Osman Joyce Kong Jonathan Ariyaratnam Mahmoud Mohamed Ismail Omran Mariely Lopez Akwe Nyabera Ian Landry Saba Iqbal Anoosh Zafar Gondal Sameen Hassan Ahmed Daoud Bahaaeldin Baraka Theo Trandafirescu Vincent Rizzo | 2021 | World Journal of Virology2021，10，4： | 2 |
| 2 | Pembrolizumab-emerging treatment of pulmonary sarcomatoid carcinoma: A case report显示文摘BACKGROUND Few studies have addressed the efficacy of pembrolizumab in pulmonary sarcomatoid carcinoma(PSC),a rare,previously rapidly fatal subtype of nonsmall-cell lung cancer.CASE SUMMARY We report the case of a 69-year-old man presented with respiratory distress caused by a large left upper lung lobe mass diagnosed as PSC with programmed death-ligand 1 expressed on more than 50 percent of tumor cells.The patient was started on pembrolizumab and,after 5 cycles,there was a more than 80 percent decrease in the size of the tumor mass.Further decrease was seen at the end of 10 cycles.The patient has been tolerating pembrolizumab well,with no limiting side-effects.Fourteen months after first coming into the hospital,he remains asymptomatic.CONCLUSION Pembrolizumab appears as a viable emerging treatment for PSC. | Emanuela Cimpeanu Jibran Ahmed Wahib Zafar Adreana DeMarinis Svetoslav S Bardarov Shamim Salman Dennis Bloomfield | 2020 | World Journal of Clinical Cases2020，8，1： | 2 |
您所在的机构暂未开通此部分的功能，请联系管理员